article Open AccessTop 1% cited

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine · 2018 · Vol. 378(22) · pp. 2078–2092

Leena Gandhi✉(NYU Langone’s Laura and Isaac Perlmutter Cancer Center)Delvys Rodríguez‐Abreu(Hospital Universitario Insular de Gran Canaria)Shirish M. Gadgeel(The Barbara Ann Karmanos Cancer Institute)Emilio Esteban(Hospital Universitario Central de Asturias)Enriqueta Felip(Vall d'Hebron Institute of Oncology)Flávia De AngelisManuel Dómine(Hospital Universitario Fundación Jiménez Díaz)Philip R. ClinganMaximilian J. Hochmair(Otto Wagner Hospital)Steven Powell(Sanford Health)Susanna Y. Cheng(Sunnybrook Health Science Centre)Helge BischoffNir Peled(Rabin Medical Center)Francesco Grossi(Ospedale Policlinico San Martino)Ross Jennens(Epworth Hospital)Martin Reck(German Center for Lung Research)Rina Hui(The University of Sydney)Edward B. Garon(University of California, Los Angeles)Michael Boyer(Chris O’Brien Lifehouse)Belén Rubio‐Viqueira(Hospital Universitario Quirónsalud Madrid)Silvia Novello(Ospedale San Luigi Gonzaga)Takayasu Kurata(Kansai Medical University)Jhanelle E. Gray(Moffitt Cancer Center)John Vida(Merck & Co., Inc., Rahway, NJ, USA (United States))Ziwen Wei(Merck & Co., Inc., Rahway, NJ, USA (United States))Jing Yang(Merck & Co., Inc., Rahway, NJ, USA (United States))Harry Raftopoulos(Merck & Co., Inc., Rahway, NJ, USA (United States))M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States))Marina Chiara Garassino(Fondazione IRCCS Istituto Nazionale dei Tumori)

View via DOI Full-text PDF

Abstract

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680 .).

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research StudiesPembrolizumabChemotherapyLung cancerMedicineOncologyInternal medicineCancerImmunotherapy

MeSH terms

Antineoplastic Agents, ImmunologicalAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDouble-Blind MethodFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedDisease-Free SurvivalKaplan-Meier Estimate